Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.

Li, Mao

Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl. [electronic resource] - Cancer chemotherapy and pharmacology May 2006 - 607-14 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

0344-5704

10.1007/s00280-005-0094-4 doi


Adamantane--analogs & derivatives
Animals
Antineoplastic Agents--pharmacokinetics
Blood Proteins--metabolism
Chromatography, High Pressure Liquid
Dogs
Drug Evaluation, Preclinical
Drug Stability
Humans
Hydroquinones--pharmacokinetics
Injections, Intraperitoneal
Injections, Intravenous
Metabolic Clearance Rate
Mice
Proto-Oncogene Proteins c-abl--antagonists & inhibitors
Proto-Oncogene Proteins c-bcr--antagonists & inhibitors
Rats
Rats, Inbred F344